3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
NIH
1
NETWORK
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
13
Neoplasm Metastasis
10
Carcinoma, Medullary
10
Thyroid Neoplasms
5
Lung Neoplasms
5
Prostatic Neoplasms
3
Neoplasms
3
Adenocarcinoma
3
Familial medullary thyroid carcinoma
2
Colorectal Neoplasms
2
Carcinoma, Squamous Cell
2
Breast Neoplasms
2
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Multiple Myeloma
1
Mesothelioma
1
Head and Neck Neoplasms
1
Gallbladder Neoplasms
1
Differentiated Thyroid Cancer
1
Colonic Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Large Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Biliary Tract Neoplasms
1
Aggression
1
Advanced Breast Cancer
1
Interventions
Paclitaxel
113
Carboplatin
99
Bevacizumab
59
pembrolizumab
56
liposomal doxorubicin
56
Gemcitabine
42
olaparib
39
Topotecan
33
niraparib
29
Nivolumab
21
Cisplatin
21
Doxorubicin
17
Cyclophosphamide
17
1-dodecylpyridoxal
16
Drug Therapy
15
Docetaxel
15
avelumab
13
Fulvestrant
11
oregovomab
10
Oxaliplatin
10
rucaparib
9
fludarabine
9
Injections
9
Fluorouracil
9
veliparib
8
mirvetuximab soravtansine
8
atezolizumab
8
Cetuximab
8
fluzoparib
7
cemiplimab
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Ovarian Neoplasms
×
vandetanib
×
Clear all
NCT00862836
2016-10-10
ZACFAST
Sanofi
Phase 1/2
Terminated
15 enrolled
13 charts